News
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The acquisition price translates to an equity value of around $3.
49m
After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.
Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...
The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity ...
Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 ...
Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.
The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...
DPA International on MSN3d
German pharma giant Merck close to takeover of US cancer specialistGermany's Merck is on the verge of a billion-euro takeover of US biopharmaceutical company Springworks Therapeutics, with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback